LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Launched by UNIVERSITY OF SYDNEY · Jan 6, 2022

Keywords

ClinConnect Summary

The LEARN trial is studying a new technology that uses a special method to track the movement of tumors and nearby organs during radiation therapy without needing any markers attached to the body. This real-time tracking can help doctors deliver more accurate treatment for various types of cancer, including breast, prostate, brain, kidney, liver, pancreas, and spinal cancers, as well as for patients with heart rhythm problems. The goal is to collect and analyze patient data to improve this tracking method over time.

To be eligible for this study, participants should be adults (18 years or older) who are scheduled to receive radiation therapy for one of the cancers mentioned above at a participating center. They will also need to undergo certain imaging tests as part of their treatment. If you decide to join the trial, you can expect to continue with your regular treatment while the new tracking method is tested alongside it, and your involvement will help improve future cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.
• • Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.
• • Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.
• • Provides written informed consent.
• Exclusion Criteria:
• • Less than 18 years of age